Production (Stage)
REGENXBIO Inc.
RGNX
$8.85
-$0.12-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 89.01M | 21.21M | 24.20M | 22.30M | 15.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 89.01M | 21.21M | 24.20M | 22.30M | 15.62M |
| Cost of Revenue | 56.52M | -151.82M | 66.82M | 15.28M | 59.13M |
| Gross Profit | 32.49M | 173.04M | -42.62M | 7.02M | -43.51M |
| SG&A Expenses | 20.35M | 15.05M | 19.42M | 18.86M | 18.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 15.00K | 833.00K | 37.00K | 29.00K | -34.00K |
| Total Operating Expenses | 76.89M | 72.58M | 86.28M | 78.33M | 77.38M |
| Operating Income | 12.13M | -51.37M | -62.08M | -56.04M | -61.76M |
| Income Before Tax | 6.08M | -51.19M | -59.60M | -52.99M | -63.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.08M | -51.19M | -59.60M | -52.99M | -63.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.08M | -51.19M | -59.60M | -52.99M | -63.33M |
| EBIT | 12.13M | -51.37M | -62.08M | -56.04M | -61.76M |
| EBITDA | 16.08M | -47.35M | -58.12M | -51.99M | -57.58M |
| EPS Basic | 0.12 | -1.01 | -1.17 | -1.05 | -1.38 |
| Normalized Basic EPS | 0.07 | -0.63 | -0.73 | -0.65 | -0.84 |
| EPS Diluted | 0.12 | -1.01 | -1.17 | -1.05 | -1.38 |
| Normalized Diluted EPS | 0.07 | -0.63 | -0.73 | -0.65 | -0.84 |
| Average Basic Shares Outstanding | 51.36M | 50.87M | 50.80M | 50.60M | 45.73M |
| Average Diluted Shares Outstanding | 51.43M | 50.87M | 50.80M | 50.60M | 45.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |